SummaryRMgm-5375
|
||||||||||
*RMgm-5375| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption, Gene tagging |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 38554111 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | RMgm-5374 |
| Other information parent line | The mutant (RMgm-5373) expresses a C-trminal, GFP-tagged version of gARID (PBANKA_0102400) |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Nishi T, Iwanaga S, Yuda M |
| Name Group/Department | Department of Medicine |
| Name Institute | Mie University |
| City | Tsu |
| Country | Japan |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5375 |
| Principal name | gARID::GFPC_gsnf2(−) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | See additional information |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Not tested |
| Sporozoite | Not tested |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Additional information To further confirm the absence of male gametocytes in garid(−), garid was knocked out in the gametocyte reporter line 820cl1 (garid[−]820), which have GFP and RFP expression cassettes under the control of male- and female-specific promoters, respectively. FACS analysis detected no GFP-positive parasites in the garid(−)820 parasites compared with the parental 820cl1 wherein approximately 3% of the parasites showed a GFP signal. This confirmed that disruption of garid results in the complete loss of male production. Notably, the genome-wide peak pattern of the ChIP-seq of gARID was almost identical to that of gSNF2, previously reported. gSNF2 is a core subunit of SWI/SNF2 chromatin remodeling complex expressed in gametocytes, and gsnf2 knockout parasite (gsnf2[−]) showed impaired male gametocyte development. However, the knockout phenotypes are of not the same; gsnf2(−) produces immature male gametocytes, whereas garid(−) completely loses the ability to differentiate into male gametocytes. In addition, female gametocyte development was affected in garid(−) but not in gsnf2(−). Consistent with the differences in their phenotype, the results in the differential expression analyses for garid(−) vs. wild type and gsnf2(−) vs. wild type were also different. A transgenic line expressing GFP-tagged gARID (gARID::GFP) was generated with the CRISPR/Cas9 system using Pbcas9, and then, gsnf2 was disrupted in the gARID::GFPC (gARID::GFPC_gsnf2(−)). Analysis is of this mutant provided evidence that gARID is recruited by gSNF2 as a subunit of the SWI/SNF complex on the TGTCT motifs. In a previous study, it was shown that the female-specific transcriptional activator, PFG, is responsible for recognizing the TGTAYRTACA motifs. Therefore, gARID is recruited to the TGTAYRTACA motifs by PFG independent of gSNF2. In addition to the ten-base motif, the TGCACA motif was also enriched around the peak summits identified in the ChIP-seq using gARID::GFPC_gsnf2(−) suggesting that it could be another important gARID-associated sequence motif. To investigate the function of the TGCACA motif as a cis-regulatory element and the relationship between the TGTCT and TGCACA motifs in male gametocyte development, reporter assays were performed using endogenous loci. As a target for the reporter assays, the following two genes were selected: calm (PBANKA_1421000, a putative calmodulin gene) as a gene significantly down-regulated in garid(−) but only slightly in gsnf2(−) and rsph9 (PBANKA_1431500, a gene encoding a putative radial spoke head protein 9 homolog, a component of radial spokes which control axonemal dynein activity) as a gene downregulated in both garid(−) and gsnf2(−) . First, each of these genes was tagged with gfp to assess their expression using FACS (CALM::GFP and RSPH9::GFP. Then, the TGTCT and TGCACA motifs were mutated, either or both, within the peak regions located upstream of calm and rsph9 to assess the roles of these two cis-regulatory elements in the activation of male genes. |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0312700 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0216000 | ||||||||||||||||||||||||
| Gene product | SNF2-like chromatin remodeling ATPase, putative | ||||||||||||||||||||||||
| Gene product: Alternative name | gSNF2, DEAD/DSNF2-like chromatin remodeling ATPase, putative | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | A transgenic line expressing GFP-tagged gARID (gARID::GFP) was generated with the CRISPR/Cas9 system using Pbcas9, and then, gsnf2 was disrupted in the gARID::GFPC (gARID::GFPC_gsnf2(−)). For tagging gARID with fluorescent proteins, knockout of garid, and knockout of gsnf2 for gARID::GFPC_gsnf2(−), the conventional homologous recombination method was used. | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0102400 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0603600 | ||||||||||||||||||||||||||
| Gene product | male development protein MD4, putative | ||||||||||||||||||||||||||
| Gene product: Alternative name | AT-rich interactive domain-containing protein, putative, gARID | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | GFP | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | |||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | A transgenic line expressing GFP-tagged gARID (gARID::GFP) was generated with the CRISPR/Cas9 system using Pbcas9, and then, gsnf2 was disrupted in the gARID::GFPC (gARID::GFPC_gsnf2(−)). | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||